PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study

BackgroundChemotherapy combined with immunotherapy or anti-vascular therapy is both recommended by guidelines for first-line treatment of lung adenocarcinoma. However, no head-to-head clinical trial has ever compared which strategy is the optimal choice. This real-world retrospective study was done...

Full description

Bibliographic Details
Main Authors: Zhe Huang, Chunhua Zhou, Yi Xiong, Feng Yang, Fanxu Zeng, Wenjuan Jiang, Yongchang Zhang, Haiyan Yang, Li Liu, Liang Zeng, Nong Yang, Zhan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
bevacizumab
chemotherapy
immune checkpoint inhibitors
NSCLC
over-all survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.909721/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.909721/full

Similar Items